Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AtriCure, Inc. stock logo
ATRC
AtriCure
$31.78
+1.2%
$32.50
$20.20
$43.11
$1.55B1.56605,921 shs166,072 shs
Atrion Co. stock logo
ATRI
Atrion
$459.92
$459.06
$274.98
$503.24
$809.46M0.6923,283 shsN/A
Cantel Medical Corp. stock logo
CMD
Cantel Medical
$80.37
$82.48
$39.40
$89.76
$3.58B1.55626,604 shsN/A
Cardiovascular Systems, Inc. stock logo
CSII
Cardiovascular Systems
$20.00
$19.98
$12.26
$20.57
$843.96M0.74765,906 shs4,300 shs
Glaukos Corporation stock logo
GKOS
Glaukos
$103.50
-0.1%
$95.71
$77.10
$163.71
$5.92B0.82739,359 shs289,937 shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AtriCure, Inc. stock logo
ATRC
AtriCure
+1.24%-3.35%-8.49%+1.50%+41.56%
Atrion Co. stock logo
ATRI
Atrion
0.00%0.00%0.00%0.00%+1.20%
Cantel Medical Corp. stock logo
CMD
Cantel Medical
0.00%0.00%0.00%0.00%0.00%
Cardiovascular Systems, Inc. stock logo
CSII
Cardiovascular Systems
0.00%0.00%0.00%0.00%0.00%
Glaukos Corporation stock logo
GKOS
Glaukos
-0.17%+2.25%+9.45%+23.77%-13.12%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AtriCure, Inc. stock logo
ATRC
AtriCure
3.3351 of 5 stars
3.55.00.00.01.42.50.6
Atrion Co. stock logo
ATRI
Atrion
N/AN/AN/AN/AN/AN/AN/AN/A
Cantel Medical Corp. stock logo
CMD
Cantel Medical
N/AN/AN/AN/AN/AN/AN/AN/A
Cardiovascular Systems, Inc. stock logo
CSII
Cardiovascular Systems
N/AN/AN/AN/AN/AN/AN/AN/A
Glaukos Corporation stock logo
GKOS
Glaukos
4.453 of 5 stars
4.41.00.04.42.71.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AtriCure, Inc. stock logo
ATRC
AtriCure
3.00
Buy$50.6759.43% Upside
Atrion Co. stock logo
ATRI
Atrion
0.00
N/AN/AN/A
Cantel Medical Corp. stock logo
CMD
Cantel Medical
0.00
N/AN/AN/A
Cardiovascular Systems, Inc. stock logo
CSII
Cardiovascular Systems
0.00
N/AN/AN/A
Glaukos Corporation stock logo
GKOS
Glaukos
2.75
Moderate Buy$134.6730.11% Upside

Current Analyst Ratings Breakdown

Latest ATRC, GKOS, CMD, ATRI, and CSII Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/6/2025
Glaukos Corporation stock logo
GKOS
Glaukos
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderweight ➝ Underweight$110.00 ➝ $72.00
5/2/2025
Glaukos Corporation stock logo
GKOS
Glaukos
Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$140.00 ➝ $115.00
5/1/2025
Glaukos Corporation stock logo
GKOS
Glaukos
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$140.00 ➝ $135.00
5/1/2025
Glaukos Corporation stock logo
GKOS
Glaukos
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$140.00 ➝ $115.00
5/1/2025
Glaukos Corporation stock logo
GKOS
Glaukos
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$176.00 ➝ $115.00
5/1/2025
Glaukos Corporation stock logo
GKOS
Glaukos
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOverweight ➝ Equal Weight$160.00 ➝ $86.00
4/30/2025
AtriCure, Inc. stock logo
ATRC
AtriCure
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$60.00 ➝ $60.00
4/30/2025
AtriCure, Inc. stock logo
ATRC
AtriCure
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$60.00 ➝ $58.00
4/30/2025
AtriCure, Inc. stock logo
ATRC
AtriCure
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$51.00 ➝ $44.00
4/16/2025
Glaukos Corporation stock logo
GKOS
Glaukos
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$200.00 ➝ $175.00
4/15/2025
Glaukos Corporation stock logo
GKOS
Glaukos
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$180.00 ➝ $165.00
(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AtriCure, Inc. stock logo
ATRC
AtriCure
$465.31M3.38N/AN/A$9.46 per share3.36
Atrion Co. stock logo
ATRI
Atrion
$181.60M4.46$19.68 per share23.37$138.02 per share3.33
Cantel Medical Corp. stock logo
CMD
Cantel Medical
$1.02B3.52$3.38 per share23.78$17.31 per share4.64
Cardiovascular Systems, Inc. stock logo
CSII
Cardiovascular Systems
$239.84M3.52N/AN/A$6.12 per share3.27
Glaukos Corporation stock logo
GKOS
Glaukos
$383.48M15.42N/AN/A$13.91 per share7.44
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AtriCure, Inc. stock logo
ATRC
AtriCure
-$44.70M-$0.81N/AN/AN/A-7.95%-5.68%-4.34%7/29/2025 (Estimated)
Atrion Co. stock logo
ATRI
Atrion
$19.41M$10.6443.23N/A10.60%7.75%7.12%N/A
Cantel Medical Corp. stock logo
CMD
Cantel Medical
$13.71M$1.6569.2828.911.634.72%12.13%4.45%N/A
Cardiovascular Systems, Inc. stock logo
CSII
Cardiovascular Systems
-$36.93M-$0.97N/AN/AN/A-15.79%-15.39%-11.93%N/A
Glaukos Corporation stock logo
GKOS
Glaukos
-$146.37M-$2.37N/AN/AN/A-31.40%-10.66%-8.06%7/30/2025 (Estimated)

Latest ATRC, GKOS, CMD, ATRI, and CSII Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/30/2025Q2 2025
Glaukos Corporation stock logo
GKOS
Glaukos
-$0.26N/AN/AN/A$115.49 millionN/A
7/29/2025Q2 2025
AtriCure, Inc. stock logo
ATRC
AtriCure
-$0.15N/AN/AN/A$130.17 millionN/A
4/30/2025Q1 2025
Glaukos Corporation stock logo
GKOS
Glaukos
-$0.33-$0.22+$0.11-$0.32$102.78 million$106.66 million
4/29/2025Q1 2025
AtriCure, Inc. stock logo
ATRC
AtriCure
-$0.25-$0.14+$0.11-$0.14$122.92 million$123.62 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AtriCure, Inc. stock logo
ATRC
AtriCure
N/AN/AN/AN/AN/A
Atrion Co. stock logo
ATRI
Atrion
$8.801.91%N/A82.71%21 Years
Cantel Medical Corp. stock logo
CMD
Cantel Medical
$0.210.26%N/A12.73%N/A
Cardiovascular Systems, Inc. stock logo
CSII
Cardiovascular Systems
N/AN/AN/AN/AN/A
Glaukos Corporation stock logo
GKOS
Glaukos
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AtriCure, Inc. stock logo
ATRC
AtriCure
0.16
4.11
2.88
Atrion Co. stock logo
ATRI
Atrion
N/A
9.18
3.06
Cantel Medical Corp. stock logo
CMD
Cantel Medical
1.16
2.72
2.00
Cardiovascular Systems, Inc. stock logo
CSII
Cardiovascular Systems
0.08
6.04
4.92
Glaukos Corporation stock logo
GKOS
Glaukos
0.09
6.49
5.62

Institutional Ownership

CompanyInstitutional Ownership
AtriCure, Inc. stock logo
ATRC
AtriCure
99.11%
Atrion Co. stock logo
ATRI
Atrion
66.19%
Cantel Medical Corp. stock logo
CMD
Cantel Medical
84.13%
Cardiovascular Systems, Inc. stock logo
CSII
Cardiovascular Systems
86.61%
Glaukos Corporation stock logo
GKOS
Glaukos
99.04%

Insider Ownership

CompanyInsider Ownership
AtriCure, Inc. stock logo
ATRC
AtriCure
3.50%
Atrion Co. stock logo
ATRI
Atrion
22.82%
Cantel Medical Corp. stock logo
CMD
Cantel Medical
10.70%
Cardiovascular Systems, Inc. stock logo
CSII
Cardiovascular Systems
3.80%
Glaukos Corporation stock logo
GKOS
Glaukos
5.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
AtriCure, Inc. stock logo
ATRC
AtriCure
1,30049.51 million47.77 millionOptionable
Atrion Co. stock logo
ATRI
Atrion
7201.76 million1.36 millionNot Optionable
Cantel Medical Corp. stock logo
CMD
Cantel Medical
3,66944.51 millionN/AOptionable
Cardiovascular Systems, Inc. stock logo
CSII
Cardiovascular Systems
78042.20 million40.59 millionOptionable
Glaukos Corporation stock logo
GKOS
Glaukos
78057.14 million53.83 millionOptionable

Recent News About These Companies

Glaukos Prepares for New Product Launches
Glaukos Corporation: Delivering Consistent Growth
Glaukos Corporation (6GJ.F)
Glaukos Trades Higher Than Medical Peers NYSE Composite
What Makes Glaukos (GKOS) a New Buy Stock

New MarketBeat Followers Over Time

Media Sentiment Over Time

AtriCure stock logo

AtriCure NASDAQ:ATRC

$31.78 +0.39 (+1.24%)
As of 07/3/2025 01:04 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure. In addition, the company sells Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.

Atrion stock logo

Atrion NASDAQ:ATRI

Atrion Corporation, together with its subsidiaries, develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmic applications in the United States, Canada, Europe, and internationally. The company's fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments. Its cardiovascular products comprise Myocardial Protection System that delivers fluids and medications, and mixes critical drugs, as well as controls temperature, pressure, and other variables; cardiac surgery vacuum relief valves; silicone vessel loops for retracting and occluding vessels; and inflation devices for balloon catheter dilation, stent deployment, and fluid dispensing, as well as products for use in heart bypass surgery. The company's ophthalmic products consist of a line of balloon catheters, which are used for the treatment of nasolacrimal duct obstruction in children and adults. It manufactures products for safe needle and scalpel blade containment; inflation systems and valves used in marine and aviation safety products; components used in inflatable survival products and structures; and one-way and two-way pressure relief valves that protect sensitive electronics and other products during transport in other medical and non-medical applications. The company sells its products to physicians, hospitals, clinics, and other treatment centers; and other equipment manufacturers through direct sales force, independent sales representatives, and distributors. Atrion Corporation was founded in 1944 and is headquartered in Allen, Texas.

Cantel Medical stock logo

Cantel Medical NYSE:CMD

Cantel Medical Corp. provides infection prevention and control products and services for the healthcare market. The company's Medical segment offers automated endoscope reprocessing systems; disinfectants and sterilants; detergents; leak testing and manual cleaning products; storage cabinets and transport systems; manual cleaning products; endoscope process tracking products; other consumables, accessories, and supplies for use in disinfect rigid endoscopes, flexible endoscopes, and other instrumentation; and technical maintenance services. Its Life Sciences segment provides dialysis water purification and bicarbonate mixing systems; hollow fiber filters, and other filtration and separation products; liquid disinfectants and cold sterilization products; dry fog products; room temperature sterilization equipment and services; and clean-room certification and decontamination services for the dialysis and other healthcare, research laboratories, food and beverage, and commercial industrial customers, as well as microbiological testing services. The company's Dental segment offers hand and powered dental instruments, instrument reprocessing and sterility assurance products, towels, bibs, tray liners, sponges, nitrous oxide/oxygen sedation equipment and related single-use disposable nasal masks, face masks, and shields. It also provides hand sanitizers, germicidal wipes, disinfectants, surface disinfectants, waterline treatment products, saliva ejectors, evacuator tips, plastic cups, prophy angles, and prophy paste. The company's Dialysis segment provides hemodialysis concentrates and other ancillary supplies; medical device reprocessing systems; and sterilants and disinfectants. The company sells its products through its direct distribution network in the United States; and directly or under various third-party distribution agreements internationally. Cantel Medical Corp. was founded in 1963 and is headquartered in Little Falls, New Jersey.

Cardiovascular Systems stock logo

Cardiovascular Systems NASDAQ:CSII

Cardiovascular Systems, Inc. is a medical device company, which engages in the development and commercialization of solutions for treating vascular and coronary disease. It offers orbital atherectomy systems for both peripheral and coronary commercial applications. The company was founded in 1989 and is headquartered in St. Paul, MN.

Glaukos stock logo

Glaukos NYSE:GKOS

$103.50 -0.13 (-0.13%)
Closing price 07/3/2025 03:30 PM Eastern
Extended Trading
$103.42 -0.08 (-0.07%)
As of 07/3/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.